Imagery Rescripting for Posttraumatic Nightmares in Rural Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans With Posttraumatic Stress Disorder (PTSD)

NCT ID: NCT00837382

Last Updated: 2010-09-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Many service members returning from Iraq and Afghanistan have difficulties adjusting back to civilian life. Research shows that symptoms of posttraumatic stress disorder (PTSD) are particularly high in returning Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) veterans, and that combat-related nightmares and sleep disturbances are common in veterans with PTSD. This is of concern because people with these problems will often use unhealthy ways of coping. Although combat-related nightmares and difficulty sleeping are highly distressing, there are helpful treatments that do not involve taking medication. One of these treatments teaches specific skills to help people improve their sleep habits and to change their nightmares so that they are less upsetting. This treatment can be very helpful and research shows that people experience decreases in the frequency and severity of their nightmares, decreased symptoms of depression and PTSD, and improved sleep quality and quantity after completing treatment. However, because this treatment has only been studied with civilians, it is not clear how well this treatment works for returning veterans. This study tests how well this treatment works in treating combat nightmares in veterans who also have PTSD from experiencing a traumatic event.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stress Disorders, Post-Traumatic Sleep Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

MEDVAMC Nightmare Treatment

Group Type EXPERIMENTAL

MEDVAMC Nightmare Treatment

Intervention Type BEHAVIORAL

Veteran Nightmare Treatment Using Imagery Rescripting

2

Videoconferencing nightmare Treatment

Group Type EXPERIMENTAL

Telepsychiatry Nightmare Treatment

Intervention Type BEHAVIORAL

Veteran Nightmare Treatment Using Imagery Rescripting Through Videoconferencing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MEDVAMC Nightmare Treatment

Veteran Nightmare Treatment Using Imagery Rescripting

Intervention Type BEHAVIORAL

Telepsychiatry Nightmare Treatment

Veteran Nightmare Treatment Using Imagery Rescripting Through Videoconferencing

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients for the open trial will be

1. OEF/OIF veterans (aged 18-64);
2. English-speaking;
3. currently enrolled in the Trauma Recovery Program (TRP) at the Michael E. DeBakey Veteran Affairs Medical Center (MEDVAMC);
4. reporting at least one combat or war zone associated PTNM in the past week;
5. have an existing PTSD International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM); and
6. consenting to be in an open trial for treatment of PTNM. In addition, patients must agree to allow their assessment and therapy sessions to be video/audiotaped for the purposes of supervision.

Pilot Study: Patients for the pilot study will be

1. OEF/OIF veterans (aged 18-64);
2. English-speaking;
3. currently enrolled in the Conroe CBOC for their primary or mental health care;
4. reporting at least one combat or war zone associated PTNM in the past week;
5. have an existing PTSD ICD-9-CM diagnosis; and
6. consenting to be in the pilot study for treatment of PTNM. In addition, patients must agree to allow their assessment and therapy sessions to be video/audiotaped for the purposes of supervision.

Exclusion Criteria

Patients will be excluded for the following reasons:

1. current active suicidal/homicidal ideation and intent;
2. current substance dependence;
3. a diagnosis of bipolar or psychosis;
4. active participation in another psychosocial treatment for PTSD;
5. prescribed the medication Prazosin (a psychotropic medication for the treatment of nightmares).

Patients interested in receiving the intervention will not be excluded if they are taking psychotropic medication (except for Prazosin) and may continue to take their medication as prescribed throughout the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

US Department of Veterans Affairs

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Department of Veterans Affairs

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mary E. Long, PhD

Role: PRINCIPAL_INVESTIGATOR

Michael E. DeBakey VA Medical Center (152)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Michael E. DeBakey VA Medical Center (152)

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H-24157

Identifier Type: -

Identifier Source: org_study_id